Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?

Lp(a)-Lowering Agents in Development: A New Era in Tackling the Burden of Cardiovascular Risk?

Lipoprotein (a) [Lp(a)] has been recognized as an independent, inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD) and aortic valve stenosis, thus representing a major target of residual CV risk. Currently, no drug has been officially approved for lowering Lp(a) levels,...

Full description

Saved in:
Bibliographic Details
Main Authors: Niki Katsiki, Michal Vrablik, Maciej Banach, Ioanna Gouni-Berthold
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Pharmaceuticals
Subjects:
lipoprotein (a)
pelacarsen
olpasiran
zerlasiran
lepodisiran
muvalaplin
Online Access:https://www.mdpi.com/1424-8247/18/5/753
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items